Genetic Exploration of the Molecular Basis of Malignancy in Adults

Completed

Conditions studied: Neoplasms

In brief

Genetic Exploration of the Molecular Basis of Malignancy in Adults.

Key facts

Study ID

NCT02416518

Run by

Sanford Health

People needed

120

Starts

2014-05-01

Expected to finish

2018-12-01

Last updated by the study team

2019-04-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Understand and provide written informed consent and HIPAA Authorization prior to initiation of any study-specific procedures.
• Have a life expectancy of >3 months.
• Have a diagnosis of metastatic, incurable cancer and have progressed on at least one line of systemic therapy OR a cancer with no standard 1st-line systemic therapy shown to prolong survival (or where a clinical trial recommended as the 1st-line option). Patients do not have to be off-treatment when enrolled on this trial. However, please see section 6.4.8 regarding the required wash-out period before starting any FDA approved on-label or off-label treatment.
• Measurable disease (RECIST 1.1).
• Be ≥18 years of age.
• ECOG Performance status 0 or 1.
• In the opinion of the investigator, be medically suitable for and willing to undergo a biopsy or surgical procedure to obtain tissue as a part of routine care for their malignancy OR have adequate archival tissue from a previous biopsy, performed no more than 14 weeks prior to enrollment, available for profiling.
• Have adequate organ and bone marrow function as defined below: Bone marrow: absolute neutrophil count (ANC) ≥ 1.5 x 109/L; hemoglobin ≥ 9 g/dL; platelets >100 x 109/L Renal: creatinine clearance ≥ 60 mL/min (calculated according to Cockcroft and Gault formula) or creatinine ≤ 1.5 mg/dL Hepatic: bilirubin ≤ 2.5 x the upper limit of normal (ULN); aspartate transaminases (AST/SGOT); alanine transaminases (ALT/SGPT) ≤ 2.5 x ULN (or ≤ 5 x ULN if due to underlying liver metastases)
• Female patients of childbearing potential must have a negative pregnancy test and agree to use at least two forms of contraception during the study and for at least one month after treatment discontinuation. For the purposes of this study, a female with child- bearing potential is defined as: any woman who meets the following criteria.
• Has not undergone a hysterectomy or bilateral oophorectomy. Has not been naturally postmenopausal for at least 24 months (i.e. has had a menses at any time in the preceding 24 consecutive months).
• Male patients must use a form of barrier contraception that contains spermicide and is approved by the investigator / treating physician during the study and for at least one month after treatment discontinuation.
• No more than one prior screening attempt for SH GEMMA.

You may not qualify if…

• Have lesions that are not accessible to biopsy or not planned for biopsy as part of routine care OR if archival tissue will be used for profiling, an insufficient amount is available OR archival tissue was obtained ≥ 14 weeks prior to enrollment.
• Have diagnosis of a hematologic malignancy.
• Diagnosis of astrocytoma, glioblastoma multiforme, or any other primary brain cancer.
• Have concurrent uncontrolled malignancy.
• Have symptomatic CNS metastasis. Patients with a history of CNS metastases who have been treated with whole brain irradiation must be stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on a stable dose of steroids for ≥ 2 weeks prior to enrollment.
• Have uncontrolled concurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
• Have known HIV, HBV, HCV infection.
• Previous enrollment in the SH GEMMA study. Patients are allowed one prior screening attempt.
• Are pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception.

Where it is running

• Sanford Health — Bemidji, Minnesota, United States
• Sanford Health — Bismarck, North Dakota, United States
• Sanford Health — Fargo, North Dakota, United States
• Sanford Health — Sioux Falls, South Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.